Literature DB >> 16003530

[Denys-Drash syndrome. Experience gathered in Erlangen illustrated by two case reports].

V Zugor1, M Zenker, J Dötsch, K M Schrott, G E Schott.   

Abstract

Denys-Drash syndrome is a rare symptom complex associated with obligatory childhood nephrotic syndrome, male pseudohermaphroditism, and Wilms' tumor. The etiology of Denys-Drash syndrome is attributed to a mutation of the WT1 gene. We report on two cases of Deny-Drash syndrome confirmed by genetic testing. Rapidly evolving terminal renal insufficiency was detected in both patients necessitating bilateral nephrectomies with prophylactic intent. In one of the patients, a Wilms' tumor had already been verified in one kidney so that chemotherapy had to be initiated.The risk of Wilms' tumor is very high in patients with a WT1 mutation, which leads to the need for removal of both kidneys during or before transplantation. It would be important to perform a diagnostic work-up for WT1 gene mutation in children who develop renal failure in the 1st year of life.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003530     DOI: 10.1007/s00120-005-0869-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  9 in total

1.  Wilms tumor in a pediatric renal transplant recipient with unexpected Denys-Drash syndrome.

Authors:  S Bydder; A Charles; I Hewitt; I Walpole; E M Algar; N Smith; M B Phillips
Journal:  Transplant Proc       Date:  2002-12       Impact factor: 1.066

Review 2.  The Denys-Drash syndrome.

Authors:  R F Mueller
Journal:  J Med Genet       Date:  1994-06       Impact factor: 6.318

3.  WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.

Authors:  N Bardeesy; B Zabel; K Schmitt; J Pelletier
Journal:  Genomics       Date:  1994-06       Impact factor: 5.736

4.  The nephropathy associated with male pseudohermaphroditism and Wilms' tumor (Drash syndrome): a distinctive glomerular lesion--report of 10 cases.

Authors:  R Habib; C Loirat; M C Gubler; P Niaudet; A Bensman; M Levy; M Broyer
Journal:  Clin Nephrol       Date:  1985-12       Impact factor: 0.975

5.  Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome).

Authors:  L Jadresic; J Leake; I Gordon; M J Dillon; D B Grant; J Pritchard; R A Risdon; T M Barratt
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

Review 6.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

7.  Prophylactic bilateral nephrectomies in two paediatric patients with missense mutations in the WT1 gene.

Authors:  Min Hu; Geoff Y Zhang; Susan Arbuckle; Nicole Graf; Albert Shun; Martin Silink; Deborah Lewis; Stephen I Alexander
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

8.  Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.

Authors:  J Pelletier; W Bruening; C E Kashtan; S M Mauer; J C Manivel; J E Striegel; D C Houghton; C Junien; R Habib; L Fouser
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

9.  Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development.

Authors:  Brigitte Royer-Pokora; Manfred Beier; Markus Henzler; Rita Alam; Valérie Schumacher; Angela Weirich; Vicki Huff
Journal:  Am J Med Genet A       Date:  2004-06-15       Impact factor: 2.802

  9 in total
  3 in total

1.  [Urogenital malformations associated with Wilms' tumor. Molecular genetic and clinical aspects].

Authors:  V Zugor; G E Schott
Journal:  Urologe A       Date:  2007-02       Impact factor: 0.639

2.  [Wilms' tumors in adults].

Authors:  V Zugor; D Krot; R Kühn; K M Schrott; G E Schott
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

3.  [Congenital urogenital malformations associated with nephroblastomas. Long-term results of a study in Erlangen].

Authors:  V Zugor; D Krot; G E Schott
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.